Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 4/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3158864 | 1.00 | EED (0.51) | EEDHRH4HRH3CHRM1HRH1 | |
| SCHEMBL3467789 | 1.00 | EED (0.51) | EEDHRH4HRH3CHRM1HRH1 | |
| Hydrochloric Acid SCHEMBL15649704 | 0.98 | EED (0.50) | EEDHRH4HRH3CHRM1HRH1 | |
| Hydrochloric Acid SCHEMBL15649703 | 0.98 | EED (0.50) | EEDHRH4HRH3CHRM1HRH1 | |
| SCHEMBL1811296 | 0.89 | GBA1 (0.52) | HRH4HRH3GBA1 | |
| Hydrochloric Acid SCHEMBL3553149 | 0.88 | GBA1 (0.50) | HRH4HRH3GBA1 | |
| SCHEMBL20015340 | 0.86 | GBA1 (0.58) | GBA1TRPA1 | |
| SCHEMBL13330901 | 0.86 | GBA1 (0.58) | GBA1TRPA1 | |
| SCHEMBL13576625 | 0.85 | KCNH2 (0.54) | EEDHRH4HRH3CHRM1HRH1 | |
| SCHEMBL13576643 | 0.83 | KCNH2 (0.53) | EEDHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| CN-104703970-A | Substituted carbamate compounds and their use as transient receptor potential (TRP) channel antagonists | HOFFMANN LA ROCHE | 2015-06-10 | — | — | CN | disclosed |
| WO-2010069979-A1 | PYRAN DERIVATIVES AS CCR3 MODULATORS | NYCOMED GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010069979-A1 | PYRAN DERIVATIVES AS CCR3 MODULATORS | NYCOMED GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| US-7550486-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550486-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550486-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7541468-B2 | Process of preparing N-ureidoalkyl-piperidines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541468-B2 | Process of preparing N-ureidoalkyl-piperidines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
| US-20020156102-A1 | Piperidine amides as modulators of chemo kine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-6444686-B1 | FOR THE PREVENTION OF ASTHMA AND OTHER ALLERGIC DISEASES. | BRSITOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-03 | — | — | US | disclosed |
| EP-1140086-A4 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARM CO (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2002002525-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001098269-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001098268-A2 | PIPERIDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001098270-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| US-6331541-B1 | TREATING ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS AND INFLAMMATORY BOWEL DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-18 | — | — | US | disclosed |
| EP-1140086-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035451-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156102-A1 | Piperidine amides as modulators of chemo kine receptor activity | CCR3, CCR1, ACKR3 | EED 2890/4885HRH4 59/4885HRH3 53/4885 |
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ACKR3, CCR7, CCR2 | EED 4388/4885HRH4 57/4885HRH3 75/4885 |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | EED 4832/4885HRH4 1452/4885HRH3 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.